Entity

Time filter

Source Type

South San Francisco, CA, United States

Patent
Talon Therapeutics | Date: 2012-06-28

This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.


Trademark
Spectrum, Talon Therapeutics and Hana Biosciences Inc. | Date: 2011-07-05

Pharmaceutical preparations, namely, drug delivery systems comprising nanoparticles that encapsulate and permit the sustained release of a wide variety of therapeutic agents. Drug delivery systems.


Trademark
Talon Therapeutics and Hana Biosciences Inc. | Date: 2010-08-25

Pharmaceutical preparations for the prevention and treatment of cancer and related symptoms.


Trademark
Talon Therapeutics | Date: 2011-05-06

Pharmaceutical preparations, namely, drug delivery systems comprising nanoparticles that encapsulate and permit the sustained release of a wide variety of therapeutic agents; drug delivery systems.


Kaplan L.D.,University of California at San Francisco | Deitcher S.R.,TALON THERAPEUTICS | Silverman J.A.,TALON THERAPEUTICS | Morgan G.,Institute of Cancer Research
Clinical Lymphoma, Myeloma and Leukemia | Year: 2014

Background VSLI (Marqibo) is active in advanced non-Hodgkin lymphoma (NHL) and untreated aggressive NHL. Because of its favorable hematologic toxicity profile, VSLI might be useful in patients unable to tolerate myelosuppressive therapies. Patients and Methods Twenty-two patients with heavily pretreated, advanced CD20+ DLBCL or MCL were treated with VSLI 2.0 mg/m 2, without a dose cap, every 2 weeks plus 4 weekly doses of rituximab 375 mg/m2. ORR, complete response (CR), or partial response (PR), was the primary end point. Secondary end points included response duration, time to progression (TTP), and OS. Safety variables included adverse events and neurologic assessments. Results The ORR was 13 of 22 (59%); 6 patients achieved a CR (27%), and 7 patients achieved a PR (32%). Median response duration, TTP, and OS were 147 days, 121 days, and 322 days, respectively. The median number of VSLI doses was 5, the median individual VSLI dose was 3.5 mg, and the maximum cumulative VSLI dose was 43 mg. Grade 3 peripheral neuropathy, febrile neutropenia, and constipation were reported in 4, 2, and 1 patients, respectively. Conclusion VSLI plus rituximab resulted in durable responses in patients with heavily pretreated advanced stage DLBCL and MCL. The toxicity profile was predictable and manageable with limited hematologic toxicity. Despite near-universal previous VCR exposure (96%) and doses of VSLI unachievable with standard VCR treatment, peripheral neuropathy and constipation were modest. This study supports further evaluation of VSLI as a component of DLBCL management. © 2014 Elsevier Inc. All rights reserved. Source

Discover hidden collaborations